Novo Nordisk, Inc · Watertown, Massachusetts
Case #I-202-24212-232054
A Associate Director, Rare Disease Research position at Novo Nordisk, Inc in Watertown, Massachusetts was filed at $205k per year, offering 13% above the prevailing wage of $181k. The case was certified in 7 days during the FY FY2024 cycle. This position is for continued employment.
| Case Number | I-202-24212-232054 |
| Case Status | Certified |
| Visa Class | H-1B1 SINGAPORE |
| Fiscal Year | FY 2024 |
| Employer | Novo Nordisk, Inc |
| Employer Location | Plainsboro, New Jersey |
| Job Title | Associate Director, Rare Disease Research |
| SOC Code | 11-912100 – Natural Sciences Managers |
| Worksite | Watertown, Massachusetts |
| Annual Wage | $205k |
| Prevailing Wage | $181k |
| Wage Premium | +13.1% |
| Positions | 1 (0 new, 0 continued) |
| Job Title | Salary | Status | Date |
|---|---|---|---|
| ASSOC DIR - DD&IT BUSINESS SOLUTIONS | $200k | CERTIFIED | Apr 7, 2025 |
| PRINCIPAL APPLICATIONS ARCHITECT - MARKETING TECHNOLOGY | $186k | CERTIFIED | Sep 4, 2025 |
| SR PROJECT MGR - IT | $179k | CERTIFIED | Sep 4, 2025 |
| SR MGR - FINANCIAL APPLICATIONS | $179k | CERTIFIED | Aug 28, 2025 |
| Associate Manager | $138k | CERTIFIED | Aug 19, 2025 |
This Labor Condition Application (LCA) was filed by Novo Nordisk, Inc for the position of Associate Director, Rare Disease Research in Watertown, Massachusetts. The offered annual salary is $205k, compared to the prevailing wage of $181k for this occupation and location. This represents a wage premium of +13.1% above the prevailing wage.
The LCA is the first step in the H-1B visa process. Employers must file an LCA with the Department of Labor certifying that they will pay the foreign worker at least the prevailing wage for the occupation in the area of intended employment. A certified LCA is required before the employer can file an H-1B petition with USCIS.
Case status: Certified. This means the Department of Labor has certified that the employer meets the wage and working condition requirements.
A Labor Condition Application (LCA) is a mandatory document that U.S. employers must file with the U.S. Department of Labor (DOL) before they can petition for a foreign worker under the H-1B, H-1B1, or E-3 visa categories. The LCA process was established under the Immigration and Nationality Act (INA) to protect both foreign and domestic workers by ensuring fair wages and working conditions.
When a U.S. company identifies a foreign national to fill a specialty occupation position, they must first obtain DOL certification through the LCA process before filing the H-1B petition (Form I-129) with U.S. Citizenship and Immigration Services (USCIS). In this case, Novo Nordisk, Inc filed LCA case number I-202-24212-232054 to sponsor a Associate Director, Rare Disease Research position at their worksite in Watertown, Massachusetts. By filing this LCA, the employer attests to four key conditions: (1) paying the higher of the actual wage or prevailing wage, (2) providing working conditions that will not adversely affect other similarly employed workers, (3) no strike or lockout at the worksite, and (4) providing notice of the filing to the bargaining representative or posting notice at the worksite.
The DOL establishes four wage levels for each occupation and geographic area, representing the progression from entry-level to fully competent workers:
For this filing, the offered wage of $205k compares to the DOL prevailing wage of $181k for Natural Sciences Managers positions in the Watertown, Massachusetts area. The positive wage premium of +13.1% indicates the employer is offering above the DOL-determined average for this occupation and location.
The prevailing wage is the average wage paid to similarly employed workers in a specific occupation in the area of intended employment. The DOL determines prevailing wages using data from the Occupational Employment and Wage Statistics (OEWS) survey conducted by the Bureau of Labor Statistics (BLS). Employers must pay H-1B workers the higher of the prevailing wage or the actual wage paid to other employees in similar positions at the company. This requirement is designed to prevent employers from using H-1B workers to undercut domestic wages.
A "Certified" status means the DOL has reviewed Novo Nordisk, Inc's attestations and determined that the LCA meets all regulatory requirements. The employer has demonstrated that the offered wage of $205k meets or exceeds the prevailing wage for Associate Director, Rare Disease Research positions in the Watertown, Massachusetts area. It is important to understand that LCA certification does not guarantee H-1B visa approval. The next step is for the employer to file Form I-129 with USCIS, which evaluates whether the position qualifies as a specialty occupation and whether the beneficiary has the required qualifications.
This LCA was received by the DOL on Jul 30, 2024 and a decision was rendered on Aug 6, 2024, a processing time of approximately 7 business days. The standard DOL processing time for LCA applications is 7 to 10 business days. This application was processed within the standard timeframe.
The offered salary of $205k for this Associate Director, Rare Disease Research position provides a data point for evaluating compensation trends in H-1B1 SINGAPORE visa sponsorship. When reviewing H-1B salary data, consider that wages vary significantly based on geographic location, employer size, industry sector, and the worker's experience level. This position falls under SOC code 11-912100 (Natural Sciences Managers), which standardizes how the Bureau of Labor Statistics classifies occupations across industries. Metropolitan areas like New York, San Francisco, and Seattle typically command higher salaries due to higher costs of living, while positions in smaller markets may offer lower nominal wages but comparable purchasing power.
The offered annual salary for this Associate Director, Rare Disease Research position at Novo Nordisk, Inc is $205k. The Department of Labor prevailing wage for this occupation and location is $181k. The offered wage represents a +13.1% premium over the prevailing wage.
This H-1B1 SINGAPORE filing is for a position located in Watertown, Massachusetts. The employing company, Novo Nordisk, Inc, is headquartered in Plainsboro, New Jersey.
This Labor Condition Application is filed under the H-1B1 SINGAPORE visa classification. This visa classification allows employers to hire foreign workers for specialty occupation positions in the United States.
The employer for this filing is Novo Nordisk, Inc, located in Plainsboro, New Jersey. Novo Nordisk, Inc filed this Labor Condition Application (case number I-202-24212-232054) for a Associate Director, Rare Disease Research position during fiscal year FY 2024. View all Novo Nordisk, Inc H-1B filings.
Certified means the U.S. Department of Labor has approved this Labor Condition Application, confirming that Novo Nordisk, Inc has attested to meeting all wage and working condition requirements. A certified LCA does not guarantee H-1B visa approval — the employer must still file a separate petition (Form I-129) with USCIS.